Eltrombopag in patients with chronic hepatitis C and thrombocytopenia

Research output: Contribution to journalArticle

Abstract

Eltrombopag is a thrombopoietic drug that acts by interacting with the TPO receptor and stimulates megakaryocytopoiesis and platelet production. Thrombocytopenia is a fairly frequent hematological abnormality in patients with chronic liver disease, and may represent an obstacle to interferon-based antiviral therapy in patients with chronic HCV infection who are otherwise good candidates for treatment. In large, multicenter, randomized, placebo-controlled studies, eltrombopag consistently enabled thrombocytopenic chronic hepatitis C patients to be treated with interferon-based therapy and, as an adjunct to antiviral therapy, has shown to be able to increase the sustained virologic response rate to treatment. The safety profile of the drug, with particular attention to the risk of thromboembolic events and the potential for hepatic decompensation, should be taken into account when planning treatment. The aim of this article is to review the information currently available regarding the pharmacokinetics, clinical efficacy and side-effect profile of eltrombopag, and to assess the role of this drug into the current and future hepatitis C treatment paradigm.

Original languageEnglish
Pages (from-to)9-20
Number of pages12
JournalFuture Virology
Volume9
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Chronic Hepatitis C
Thrombocytopenia
Interferons
Therapeutics
Antiviral Agents
Pharmaceutical Preparations
Thrombopoiesis
Hepatitis C
eltrombopag
Liver Diseases
Chronic Disease
Blood Platelets
Pharmacokinetics
Placebos
Safety
Liver
Infection

Keywords

  • chronic liver disease
  • HCV
  • hepatitis C virus
  • interferon
  • platelets
  • ribavirin
  • sustained virologic response

ASJC Scopus subject areas

  • Virology

Cite this

Eltrombopag in patients with chronic hepatitis C and thrombocytopenia. / Giannini, Edoardo G.

In: Future Virology, Vol. 9, No. 1, 01.2014, p. 9-20.

Research output: Contribution to journalArticle

@article{fc09ea54946245e1b93eff664af864f4,
title = "Eltrombopag in patients with chronic hepatitis C and thrombocytopenia",
abstract = "Eltrombopag is a thrombopoietic drug that acts by interacting with the TPO receptor and stimulates megakaryocytopoiesis and platelet production. Thrombocytopenia is a fairly frequent hematological abnormality in patients with chronic liver disease, and may represent an obstacle to interferon-based antiviral therapy in patients with chronic HCV infection who are otherwise good candidates for treatment. In large, multicenter, randomized, placebo-controlled studies, eltrombopag consistently enabled thrombocytopenic chronic hepatitis C patients to be treated with interferon-based therapy and, as an adjunct to antiviral therapy, has shown to be able to increase the sustained virologic response rate to treatment. The safety profile of the drug, with particular attention to the risk of thromboembolic events and the potential for hepatic decompensation, should be taken into account when planning treatment. The aim of this article is to review the information currently available regarding the pharmacokinetics, clinical efficacy and side-effect profile of eltrombopag, and to assess the role of this drug into the current and future hepatitis C treatment paradigm.",
keywords = "chronic liver disease, HCV, hepatitis C virus, interferon, platelets, ribavirin, sustained virologic response",
author = "Giannini, {Edoardo G.}",
year = "2014",
month = "1",
doi = "10.2217/fvl.13.115",
language = "English",
volume = "9",
pages = "9--20",
journal = "Future Virology",
issn = "1746-0794",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Eltrombopag in patients with chronic hepatitis C and thrombocytopenia

AU - Giannini, Edoardo G.

PY - 2014/1

Y1 - 2014/1

N2 - Eltrombopag is a thrombopoietic drug that acts by interacting with the TPO receptor and stimulates megakaryocytopoiesis and platelet production. Thrombocytopenia is a fairly frequent hematological abnormality in patients with chronic liver disease, and may represent an obstacle to interferon-based antiviral therapy in patients with chronic HCV infection who are otherwise good candidates for treatment. In large, multicenter, randomized, placebo-controlled studies, eltrombopag consistently enabled thrombocytopenic chronic hepatitis C patients to be treated with interferon-based therapy and, as an adjunct to antiviral therapy, has shown to be able to increase the sustained virologic response rate to treatment. The safety profile of the drug, with particular attention to the risk of thromboembolic events and the potential for hepatic decompensation, should be taken into account when planning treatment. The aim of this article is to review the information currently available regarding the pharmacokinetics, clinical efficacy and side-effect profile of eltrombopag, and to assess the role of this drug into the current and future hepatitis C treatment paradigm.

AB - Eltrombopag is a thrombopoietic drug that acts by interacting with the TPO receptor and stimulates megakaryocytopoiesis and platelet production. Thrombocytopenia is a fairly frequent hematological abnormality in patients with chronic liver disease, and may represent an obstacle to interferon-based antiviral therapy in patients with chronic HCV infection who are otherwise good candidates for treatment. In large, multicenter, randomized, placebo-controlled studies, eltrombopag consistently enabled thrombocytopenic chronic hepatitis C patients to be treated with interferon-based therapy and, as an adjunct to antiviral therapy, has shown to be able to increase the sustained virologic response rate to treatment. The safety profile of the drug, with particular attention to the risk of thromboembolic events and the potential for hepatic decompensation, should be taken into account when planning treatment. The aim of this article is to review the information currently available regarding the pharmacokinetics, clinical efficacy and side-effect profile of eltrombopag, and to assess the role of this drug into the current and future hepatitis C treatment paradigm.

KW - chronic liver disease

KW - HCV

KW - hepatitis C virus

KW - interferon

KW - platelets

KW - ribavirin

KW - sustained virologic response

UR - http://www.scopus.com/inward/record.url?scp=84893877294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893877294&partnerID=8YFLogxK

U2 - 10.2217/fvl.13.115

DO - 10.2217/fvl.13.115

M3 - Article

AN - SCOPUS:84893877294

VL - 9

SP - 9

EP - 20

JO - Future Virology

JF - Future Virology

SN - 1746-0794

IS - 1

ER -